Neumora, enGene cut staff in cost-saving initiatives
Neuroscience biotech Neumora and genetic medicines company enGene both announce workforce reductions as part of cost-saving initiatives amid a broader sector pullback.
Neumora Therapeutics is a clinical-stage neuroscience company developing precision medicines for brain diseases with high unmet need. Its lead asset NMRA-140 (navacaprant) is a kappa opioid receptor antagonist studied in major depressive disorder, and the company has additional programs in schizophrenia and other CNS indications. Following two Phase 3 failures in mid-2026, Neumora announced a 35% workforce reduction and is discontinuing development of its lead depression asset.
Company Info
Upcoming Milestones & Key Dates
Completion of 35% workforce reduction and pipeline restructuring
Strategic review of remaining pipeline and cash runway guidance
Clinical Development Pipeline
Recent News
Neuroscience biotech Neumora and genetic medicines company enGene both announce workforce reductions as part of cost-saving initiatives amid a broader sector pullback.
Neumora Therapeutics is laying off 35% of its workforce and discontinuing its lead depression drug after the asset failed two Phase 3 trials, sending shares down sharply and forcing a major pipeline reset.
Endpoints News exclusive: Neumora Therapeutics is cutting 35% of staff and shelving its lead depression drug after two more Phase 3 trials missed, the latest in a wave of high-profile central nervous system setbacks.
Leadership Team
President and Chief Executive Officer
Chief Medical Officer
Chief Scientific Officer
Careers & Job Openings